Hepatitis C Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Hepatitis C Market Analysis

The hepatitis C market is poised to register a CAGR of 12.82% over the forecast period.

• The COVID-19 pandemic significantly impacted the hepatitis C market and influenced the market growth rate during the pandemic phase. For instance, according to a study published by the Journal of Managed Care & Specialty Pharmacy in June 2022, patients with hepatitis C (HCV) had poorer access to treatment. They were much less likely to complete the treatment course amid the COVID-19 pandemic. The study observed decreased adherence to HCV DAA therapy and laboratory monitoring through the outbreak phase.
• Furthermore, the above study highlighted the telehealth option for patients in a post-COVID-19 environment that could provide an additional advantage in increasing access to care for patients with HCV. Hence, with better access to diagnosis and treatment post-COVID-19, the demand for hepatitis C tests and drugs observed a nominal increase. For instance, according to an article published by Inquiry in May 2023, the COVID-19 pandemic enhanced the use of telehealth to deliver services to those with hepatitis C virus (HCV), human immunodeficiency virus (HIV), and other chronic diseases in need of this type of care.
• Additionally, there was a post-pandemic acceptability of pharmacist-delivered telehealth services among HCV and HIV monoinfected and coinfected patients. Thus, as per the analysis, the impact of COVID-19 was severe in the initial stages of the outbreak; however, with increased awareness and growth in the accessibility of digital options such as telehealth in the post-pandemic era, the market is anticipated to witness stable growth over the coming years.
• Factors such as the growing disease burden of hepatitis C, increasing awareness and advances in diagnosis, and a surge in the availability of advanced therapeutic products are expected to drive market growth. For instance, according to the World Health Organization (WHO) update in June 2022, an estimated 58 million people had chronic hepatitis C virus infection, with about 1.5 million new infections occurring every year globally. An estimated 3.2 million adolescents and children had chronic hepatitis C infection. Thus, with a high burden of hepatitis C, the demand for its treatment and early diagnosis increases, leading to market growth.
• Furthermore, according to an article published by Current Opinion in Infectious Diseases, in July 2022, direct-acting antiviral (DAA) regimens targeting hepatitis C virus (HCV) were approved for young children. Postpartum treatment programs prevent vertical transmission but are hampered by low linkage rates to care and treatment completion. These challenges were avoided by DAA use in pregnancy. Thus, with the advancement in treatment modalities for hepatitis C, the demand for these is also expected to increase, driving market growth.
• Furthermore, May 2022 was observed as Hepatitis Awareness Month to raise awareness about, recognize the impact of, and decrease the stigma associated with viral hepatitis in the United States. Also, in September 2021, NACCHO partnered with NASTAD and the National Viral Hepatitis Roundtable to launch the Hepatitis Network for Education and Testing (HepNET) to identify and address the unmet needs of people who inject drugs (PWID) and improve their access to viral hepatitis education, prevention, testing, linkage to care, and treatment. Thus, with increasing awareness, the demand for hepatitis C diagnosis and treatment will likely increase, boosting market growth.
• Thus, all factors mentioned above are expected to boost market growth over the forecast period. However, the higher cost of treatment, social stigma, and undiagnosed cases are restraining the market growth.

Hepatitis C Market Trends

Antiviral Drugs Segment is Expected to Hold a Major Share in the Hepatitis C Market

Hepatitis C Industry Segmentation

Hepatitis C is a viral infection that causes liver inflammation, sometimes leading to severe liver damage. Hepatitis C testing and therapeutic interventions are essential components in managing hepatitis C.

The hepatitis C market is segmented by type (diagnosis (liver biopsy, blood tests, and other diagnoses) and treatment (antiviral drugs, immune modulator drugs, and other treatments)), end-user (hospitals and clinics, diagnostic laboratories, and other end-users), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.

The report offers the value (in USD) for the above segments.